Skip to main content
. Author manuscript; available in PMC: 2022 Oct 11.
Published in final edited form as: Nat Cell Biol. 2022 Apr 11;24(4):554–564. doi: 10.1038/s41556-022-00877-0

Figure 5. PRC2 dysfunction is associated with poor prognosis of breast cancer patients.

Figure 5.

a, OncoPrint (cBioPortal) showing patients with loss of function mutations of PRC2 component genes in the TCGA breast cancer patient cohort. b, Kaplan-Meier survival (log rank Mantel-Cox test) of TCGA breast cancer patients with or without loss of function mutations of PRC2 component genes. c, OncoPrint (cBioPortal) showing patients with loss of function mutations of KMT2D-COMPASS component genes in TCGA breast patient cohort. d, Kaplan-Meier survival (log rank Mantel-Cox test) of TCGA breast cancer patients with or without loss of function mutations of KMT2D-COMPASS component genes. e, The EED-KO gene signature consisting PRC2 direct target genes that were uniquely up-regulated in C1-sgEED quasi-mesenchymal cell population. f,g, Kaplan-Meier survival (log rank Mantel-Cox test) of total (f) or ER-negative (g) breast cancer patients with high or low EED-KO signature scores.